- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 163706-36-3] Cangrelortetrasodium
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-19638A |
| Brand: | MCE |
| CAS: | 163706-36-3 |
Overview
| MDL | MFCD14635359 |
|---|---|
| Molecular Weight | 864.29 |
| Molecular Formula | C17H21Cl2F3N5Na4O12P3S2 |
| SMILES | O[C@H]1[C@@H](O)[C@H](N2C3=NC(SCCC(F)(F)F)=NC(NCCSC)=C3N=C2)O[C@@H]1COP(OP(C(Cl)(P(O[Na])(O[Na])=O)Cl)(O[Na])=O)(O[Na])=O |
1 Publications Citing Use of MCE
Summary
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist [1] [2] .
IC50 & Target
|
P2Y12 Receptor
|
In Vitro
In Vivo
Cangrelor tetrasodium (10 mg/kg) not only significantly decreases BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreases the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02978040 | University Hospital Inselspital, Berne |
Coronary Artery Disease|STEMI - ST Elevation Myocardial Infarction
|
July 4, 2017 | Phase 4 |
| NCT01979445 | The Medicines Company |
Coronary Artery Disease (CAD)
|
December 2, 2013 | Phase 2 |
| NCT04138641 | Isala |
STEMI - ST Elevation Myocardial Infarction|NSTEMI - Non-ST Segment Elevation MI|Coronary Artery Disease
|
December 17, 2019 | |
| NCT03182855 | University of Aarhus |
Acute Coronary Syndrome|Myocardial Infarction|STEMI - ST Elevation Myocardial Infarction
|
September 1, 2018 | Phase 4 |
| NCT05505591 | Universita degli Studi di Genova|Università degli Studi della Campania Luigi Vanvitelli |
Bleeding|Coronary Artery Disease|Myocardial Infarction
|
June 6, 2022 | |
| NCT04790032 | Federico II University |
Percutaneous Coronary Intervention
|
March 16, 2021 | |
| NCT04667078 | Fondation Ophtalmologique Adolphe de Rothschild|Ministry of Health, France |
Acute Ischemia
|
March 2, 2022 | Phase 3 |
| NCT01766466 | The Medicines Company |
Coronary Artery Disease
|
January 2013 | Phase 2 |
| NCT04668144 | University of Florida|Scott R. MacKenzie Foundation |
Coronary Artery Disease|Acute Coronary Syndrome
|
February 9, 2021 | Phase 4 |
| NCT03247738 | University of Florida|Chiesi Farmaceutici S.p.A. |
ST Segment Elevation Myocardial Infarction|Percutaneous Coronary Intervention
|
November 20, 2017 | Phase 4 |
| NCT00699504 | The Medicines Company |
Healthy
|
June 2008 | Phase 1 |
| NCT03862651 | Ospedale Santa Croce-Carle Cuneo |
Platelet Aggregation Inhibitors
|
June 1, 2019 | Phase 2 |
| NCT03273075 | Medical University of Vienna |
Cardiopulmonary Arrest With Successful Resuscitation|ACS - Acute Coronary Syndrome|Hypothermia, Induced
|
September 2017 | Phase 4 |
| NCT04927949 | University Hospital, Caen|Terumo Medical Corporation |
ST-elevation Myocardial Infarction
|
June 8, 2021 | Phase 4 |
| NCT03043274 | Khaled Ziada, MD|University of Kentucky |
STEMI - ST Elevation Myocardial Infarction
|
January 2017 | Phase 4 |
| NCT02733341 | The Royal Wolverhampton Hospitals NHS Trust |
Acute Coronary Syndrome (ACS)|High On-treatment Platelet Reactivity (HTPR)|Microvascular Obstruction (MVO)|ST-segment Elevation Myocardial Infarction (STEMI)|Thrombolysis in Myocardial Infarction (TIMI)|Unstable Angina (UA)
|
July 21, 2016 | Phase 4 |
| NCT04005729 | University Medical Centre Ljubljana|Chiesi Slovenija, d.o.o. |
Out-Of-Hospital Cardiac Arrest|Acute Coronary Syndrome
|
July 1, 2019 | Phase 4 |
| NCT00102674 | The Medicines Company |
Healthy
|
March 2005 | Phase 1 |
| NCT01156571 | The Medicines Company |
Atherosclerosis|Percutaneous Coronary Intervention|Acute Coronary Syndrome
|
September 2010 | Phase 3 |
| NCT00305162 | The Medicines Company |
Myocardial Infarction (MI)|Acute Coronary Syndromes (ACS)
|
April 2006 | Phase 3 |
| NCT04634162 | University of Florida|Scott R. MacKenzie Foundation |
Coronary Artery Disease
|
February 9, 2021 | Phase 4 |
| NCT03551964 | Faculty Hospital Kralovske Vinohrady|Charles University, Czech Republic |
Acute Myocardial Infarction|Cardiogenic Shock
|
August 1, 2018 | Phase 4 |
| NCT02765633 | Chiesi Farmaceutici S.p.A. |
Partial Obstruction of Systemic to Pulmonary Artery Shunt|Complete Obstruction of Systemic to Pulmonary Artery Shunt
|
January 3, 2017 | Phase 1 |
| NCT03102723 | National Heart Centre Singapore|Tan Tock Seng Hospital|National University Hospital, Singapore|Khoo Teck Puat Hospital|Changi General Hospital|Sengkang General Hospital |
STEMI
|
October 1, 2017 | Phase 2 |
| NCT00385138 | The Medicines Company |
Atherosclerosis|Acute Coronary Syndrome (ACS)
|
September 2006 | Phase 3 |
| NCT02943369 | Attikon Hospital|AHEPA University Hospital|University Hospital, Alexandroupolis |
STEMI
|
July 28, 2017 | Phase 4 |
| NCT01852019 | The Medicines Company |
Coronary Artery Disease
|
June 2013 | Phase 2 |
| NCT00767507 | The Medicines Company |
Acute Coronary Syndrome (ACS)
|
October 2008 | Phase 2 |
| NCT03048019 | Inova Health Care Services |
Non-ST Elevation Myocardial Infarction (NSTEMI)
|
August 23, 2017 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
H 2 O : 125 mg/mL ( 144.63 mM ; Need ultrasonic)
DMSO : 12.5 mg/mL ( 14.46 mM ; ultrasonic and warming and heat to 80°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.1570 mL | 5.7851 mL | 11.5702 mL |
| 5 mM | 0.2314 mL | 1.1570 mL | 2.3140 mL |
| 10 mM | 0.1157 mL | 0.5785 mL | 1.1570 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (115.70 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 1.25 mg/mL (1.45 mM); Clear solution; Need ultrasonic
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: 1.25 mg/mL (1.45 mM); Clear solution; Need ultrasonic
References
- [1] Bhattad VB, , et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019;7(17):408.
- [2] Zhan T, Wei T, et al. Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice. Mol Immunol. 2020;120:83-92.
- [3] Bekő K, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain. J Thromb Haemost. 2017;15(6):1223-1235.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.